Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130386 | 0.96 | LMNA (0.50) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| Hydrochloric Acid SCHEMBL2554902 | 0.96 | LMNA (0.55) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL17586276 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL13736300 | 0.92 | — | — | |
| SCHEMBL24243950 | 0.83 | LMNA (0.41) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL18543255 | 0.83 | LMNA (0.41) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL18543254 | 0.83 | LMNA (0.41) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL3332166 | 0.83 | LMNA (0.41) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| Hydrochloric Acid SCHEMBL1071784 | 0.81 | LMNA (0.43) | LMNAGRIN1GRIN2ASLC22A1GRIN2D | |
| SCHEMBL5166320 | 0.79 | GRIN1 (0.43) | LMNAGRIN1GRIN2ASLC22A1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | claimed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | claimed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | claimed |
| EP-2389351-A1 | A PROCESS FOR PREPARING MEMANTINE | Merz Pharma GmbH & Co. KGaA (DE) | 2011-11-30 | — | — | EP | claimed |
| US-20110282100-A1 | PROCESS FOR PREPARING MEMANTINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-11-17 | — | — | US | claimed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | claimed |
| US-8041802-B2 | Decoupled logical and physical data storage within a database management system | TERADATA US, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2010083996-A1 | A PROCESS FOR PREPARING MEMANTINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-07-29 | — | — | WO | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | LMNA 4013/4885GRIN1 1/4885GRIN2A 2/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | LMNA 3937/4885GRIN1 2/4885GRIN2A 1/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | LMNA 837/4885GRIN1 14/4885GRIN2A 13/4885 |
| US-20110282100-A1 | PROCESS FOR PREPARING MEMANTINE | PSEN2, SLC6A2, PNMT | LMNA 430/4885GRIN1 46/4885GRIN2A 7/4885 |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | LMNA 3107/4885GRIN1 958/4885GRIN2A 870/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | LMNA 926/4885GRIN1 207/4885GRIN2A 134/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | LMNA 1900/4885GRIN1 24/4885GRIN2A 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.